Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchialla P, Arena S, Buzzetti R, Avogaro A; DARWIN-T2D network. Fadini GP, et al. Diabetes Obes Metab. 2019 Aug;21(8):1886-1894. doi: 10.1111/dom.13747. Epub 2019 May 8. Diabetes Obes Metab. 2019. PMID: 30985052 Free PMC article.
Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Maddaloni E, Coraggio L, Amendolara R, Baroni MG, Cavallo MG, Copetti M, Cossu E, D'Angelo P, D'Onofrio L, Cosmo S, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Park K, Holman RR, Trischitta V, Buzzetti R; SUMMER Study in Diabetes Group. Maddaloni E, et al. Diabetes Metab Res Rev. 2023 Jul;39(5):e3632. doi: 10.1002/dmrr.3632. Epub 2023 Mar 20. Diabetes Metab Res Rev. 2023. PMID: 36880127
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
Validation in type 2 diabetes of a metabolomic signature of all-cause mortality.
Copetti M, Baroni MG, Buzzetti R, Cavallo MG, Cossu E, D'Angelo P, Cosmo S, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Savino AF, Trischitta V. Copetti M, et al. Diabetes Metab Res Rev. 2024 Feb;40(2):e3734. doi: 10.1002/dmrr.3734. Epub 2023 Oct 15. Diabetes Metab Res Rev. 2024. PMID: 37839040
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2024 Mar 23:S0939-4753(24)00125-X. doi: 10.1016/j.numecd.2024.03.023. Online ahead of print. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036 Free article.
Dispersion patterns of SARS-CoV-2 variants Gamma, Lambda and Mu in Latin America and the Caribbean.
Gräf T, Martinez AA, Bello G, Dellicour S, Lemey P, Colizza V, Mazzoli M, Poletto C, Cardoso VLO, da Silva AF; COVIGEN; Motta FC, Resende PC, Siqueira MM, Franco L, Gresh L, Gabastou JM, Rodriguez A, Vicari A, Aldighieri S, Mendez-Rico J, Leite JA. Gräf T, et al. Nat Commun. 2024 Feb 28;15(1):1837. doi: 10.1038/s41467-024-46143-9. Nat Commun. 2024. PMID: 38418815 Free PMC article.
343 results